<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115815">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01677468</url>
  </required_header>
  <id_info>
    <org_study_id>2011-12-122</org_study_id>
    <nct_id>NCT01677468</nct_id>
  </id_info>
  <brief_title>Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Carcinoma</brief_title>
  <official_title>Phase Study About Feeding Artery Obliteration by Chemoembolization on Survival of Patients With Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hallym University Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate whether survival of patients who underwent TACE with
      unresectable HCC can benefit from intermediate-levels of embolization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjective angiographic chemoembolization endpoints (SACE) levels were developed to
      standardize the embolic endpoints of transarterial chemoembolization (TACE) for
      hepatocellular carcinoma (HCC). It determined the antegrade arterial flow and residual tumor
      blush as follows: I, normal-normal; II, reduced-reduced; III, reduced-none; IV, none-none.
      SACE level II and III indicates intermediate-levels of embolization, whereas IV indicates
      overembolization. The aim of this study was to evaluate whether survival of patients who
      underwent TACE with unresectable HCC can benefit from intermediate-levels of embolization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Survival rate of the subjects</measure>
    <time_frame>6 months after TACE</time_frame>
    <safety_issue>No</safety_issue>
    <description>Survival rate of the subjects 6 months after TACE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival rate of the subjects</measure>
    <time_frame>12 months after TACE</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Survival rate of the subjects, 12 months after TACE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival rate of the subjects</measure>
    <time_frame>18 months after  TACE</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Survival rate of the subjects, 18 months after  TACE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival rate of the subjects</measure>
    <time_frame>24 months after  TACE</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Survival rate of the subjects, 24 months after  TACE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival of the subjects</measure>
    <time_frame>6, 12, 18, and 24 months after TACE</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disease free survival of the subjects, 24 months after TACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate of TACE</measure>
    <time_frame>6, 12, 18, and 24 months after TACE</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The incidence of infection, hemorrhage, 24 months after TACE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Transarterial Chemoembolization</condition>
  <arm_group>
    <arm_group_label>Intermediate embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TACE with substatsis using gelfoam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Complete embolization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TACE with complete embolization using gelfoam</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intermediate embolization</intervention_name>
    <description>TACE with substasis using gelfoam</description>
    <arm_group_label>Intermediate embolization</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>Cysplatin</other_name>
    <other_name>Gelfoam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Complete embolization</intervention_name>
    <description>TACE with complete embolization using gelfoam</description>
    <arm_group_label>Complete embolization</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>Cysplatin</other_name>
    <other_name>Gelfoam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age over 18

          -  ECOG performance status 0-2

          -  Hepatocellular carcinoma diagnosed histologically or clinically

          -  Tumor numbers of 5 or less

          -  No history of treatment for hepatocellular carcinoma

          -  Patients with informed consent

        Exclusion Criteria:

          -  Extrahepatic metastasis

          -  Rupture of hepatocellular carcinoma

          -  Infiltrative hepatocellular carcinoma

          -  Malignancy other than hepatocellular carcinoma
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Hoon Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang Hoon Park, M.D., Ph.D.</last_name>
    <phone>82-2-829-5493</phone>
    <email>dr.sanghoon.park@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Su Rin Shin, M.D.</last_name>
    <phone>82-2-829-5490</phone>
    <email>dr.goforit@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hallym Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <zip>431070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Choong Kee Park, M.D., Ph.D.</last_name>
      <phone>82-31-380-3708</phone>
      <email>ckp@hallym.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chuncheon Sacred Heart Hospital</name>
      <address>
        <city>Chuncheon</city>
        <zip>200060</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Joon Kim, M.D., Ph.D.</last_name>
      <phone>82-33-741-1226</phone>
      <email>djkim@hallym.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kangnam Sacred Heart Hostpita</name>
      <address>
        <city>Seoul</city>
        <zip>150950</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Hoon Park, M.D., Ph.D.</last_name>
      <phone>82-2-829-5493</phone>
      <email>dr.sanghoon.park@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sang Hoon Park, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 29, 2012</lastchanged_date>
  <firstreceived_date>August 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Transarterial chemoembolization</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Gelatin Sponge, Absorbable</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
